Teleflex Launches New Arrow Pressure Injectable Midline

WAYNE, Pa., June 07, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), one of the world’s leading medical technology providers, today announced the launch of an Arrow Pressure-Assisted Injectable Midline Catheter in Europe, Middle East and Africa Region. The addition of the Pressure Injectable Catheter further enhances the Midline portfolio to meet the expanded needs of clinicians and is designed to improve patient safety.

The new Arrow 20cm Pressure Injectable Midline with bright yellow hubs and labeling will help clinicians overcome catheter identification confusion, which can lead to infusion errors that can harm patients. Additional features include:

  • Available in 1 and 2 light configurations
  • TAPERFREE design, which ensures a constant French size from the distal end to the hub of the catheter to reduce the risk of venous stasis. This design is aligned with INS standards for selecting a catheter with a catheter to vein ratio of 45% or less from the distal end to the hub
  • Tray configuration designed to facilitate procedural efficiency
  • Arrow Ergonomic trimmer that allows multiple and precise cuts with its window for easy viewing of centimeter markings on the catheter
  • Additional sharps safety components to meet INS standards

“The new catheter design is a direct result of our partnership with clinicians and illustrates how we work together to identify needs and develop solutions that help them improve patient care,” said Matthew James, President EMEA. from Teleflex. “We are excited to bring the Arrow Pressure Injectable Midline Catheter to market in the region and expand our portfolio to meet the many vascular access needs.

The new Arrow Pressure Injectable Midline enables up to 5ml/second pressure injection through either lumen to mitigate diagnostic and treatment delays associated with secondary device replacement.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve people’s health and quality of life. We apply goal-driven innovation – a relentless pursuit of identifying unmet clinical needs – for the benefit of patients and healthcare providers. Our portfolio is diverse, with solutions in Vascular Access, Interventional Cardiology and Radiology, Anesthesia, Emergency Medicine, Surgery, Urology and Respiratory Care . Teleflex employees around the world are united in the understanding that what we do every day makes a difference. For more information, visit

Teleflex is the headquarters of Arrow, Deknatel, LMA®Pilling, QuikClot, Rüsch, UroLift and Weck – trusted brands united by a common goal.

Forward-looking statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. All forward-looking statements contained herein are based on the current beliefs and expectations of our management, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or of the company materially different from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, Weck and TAPERFREE are trademarks or registered trademarks of Teleflex Incorporated or its subsidiaries, in the United States and/or other countries .

© 2022 Teleflex Incorporated. All rights reserved. MCI-100825 Rev 1 05 22

Teleflex Incorporated:

Laurent Keusch
Vice President, Investor Relations and Strategic Development

John Hsu, CFA
Vice President, Investor Relations

Previous Personal loan rates drop slightly for 5-year fixed rate loans
Next Texas reports first case of monkeypox in Dallas County